TherapeuticsMD, Inc.

CIK 25743 TXMD·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

2026-01-21 Auditor change 8-K
2026-03-30 Going concern 10-K +68d
2026-04-01 Late filing NT 10-K +2d

Refine

An amendment is grouped with the report it amends; every 12b-25 notice is one group

Late filing high Filing comparison 2026-04-01

TherapeuticsMD, Inc. told the SEC it could not file its annual report on time

Does not expect a significant change in results. 1 day past the statutory due date.

(the “Company”) is unable to file its Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K”) without unreasonable effort or expense within the time period prescribed. Due to an inadvertent printer error, the 2025 Form 10-K was filed on March 30, 2026 without the report of the Company’s predecessor independent registered public accounting firm, Berkowitz Pollack Brant, Advisors + CPAs, on the consolidated financial statements as of and for the year ended December 31, 2024. The Company added the report of Berkowitz Pollack Brant, Advisors + CPAs and made certain other printer corrections, including to update hyperlinks.

Evidence

Anticipates significant change: No
Days past due date: 1
Other periodic reports filed: Yes
Routine: No
Severity: high
Source: Form 12b-25 (notification of late filing)
Stated reason: (the “Company”) is unable to file its Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K”) without unreasonable effort or expense within the time period prescribed. Due to an inadvertent printer error, the 2025 Form 10-K was filed on March 30, 2026 without the report of the Company’s predecessor independent registered public accounting firm, Berkowitz Pollack Brant, Advisors + CPAs, on the consolidated financial statements as of and for the year ended December 31, 2024. The Company added the report of Berkowitz Pollack Brant, Advisors + CPAs and made certain other printer corrections, including to update hyperlinks.
Why: The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Going concern Filing comparison 2026-03-30

TherapeuticsMD, Inc. disclosed substantial doubt about its ability to continue as a going concern

No going-concern disclosure → Substantial doubt about ability to continue as a going concern

See “Going Concern” above for further discussion related to our ability to generate and obtain adequate amounts of cash to meet our liquidity needs and our plans to satisfy our such needs in the short-term and in the long-term. As a result, there is substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of the financial statements included in this 2025 10-K Report. Cash flows The following table reflects the major categories of cash flows from continuing operations for each of the periods (in thousands). Years ended December 31, Cash…

Evidence

Blank check: No
Comparable: Yes
Current state: substantial_doubt
Current state label: Substantial doubt about ability to continue as a going concern
Direction: escalated
Located in: going-concern note
Prior filed: 2025-04-30
Prior form: 10-K/A
Prior state: none
Prior state label: No going-concern disclosure
Source: ASC 205-40 going-concern note comparison
Why: Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

Auditor change SEC item code 2026-01-21

TherapeuticsMD, Inc. reported a change in its independent accounting firm

The company dismissed the auditor.

Evidence

Direction: dismissed
Direction label: The company dismissed the auditor
Item code: 4.01
Item title: Changes in Registrant's Certifying Accountant
Severity: normal
Source: SEC 8-K item code
Why: The company's independent registered accounting firm changed.

Source filing ↗